Sebastian Bauer
塞巴斯蒂安·鲍尔
MD
Professor of Medical Oncology; Head, Sarcoma Center
👥Biography 个人简介
Sebastian Bauer, MD is Professor of Medical Oncology and Head of the Sarcoma Center at University Hospital Essen, Germany. He is a world-leading authority on the molecular biology and targeted therapy of gastrointestinal stromal tumors (GIST), with particular expertise in resistance mechanisms to KIT/PDGFRA inhibitors and the clinical development of next-generation GIST-targeted agents. His laboratory and clinical programs have been central to defining the molecular landscape of secondary KIT resistance mutations and to the development of ripretinib and avapritinib as approved treatments for advanced GIST. Dr. Bauer has been a principal investigator in the INVICTUS trial of ripretinib, the NAVIGATOR trial of avapritinib for PDGFRA D842V-mutant GIST, and multiple other registrational studies. He serves in leadership roles within the EORTC Soft Tissue and Bone Sarcoma Group and the German Interdisciplinary Sarcoma Group (GISG), and has authored over 200 peer-reviewed publications.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Avapritinib for PDGFRA D842V-Mutant GIST
Principal investigator and key contributor to the NAVIGATOR phase I trial of avapritinib, demonstrating unprecedented response rates exceeding 85% in patients with PDGFRA D842V-mutant GIST—a historically imatinib-resistant genotype—leading to FDA breakthrough designation and approval.
Ripretinib as Fourth-Line GIST Therapy
Led the European contribution to the INVICTUS phase III trial demonstrating that ripretinib, a switch-control KIT/PDGFRA inhibitor, significantly improved progression-free survival versus placebo in patients with advanced GIST after three or more prior therapies, supporting regulatory approval.
Molecular Mechanisms of Secondary KIT Resistance
Conducted landmark molecular studies characterizing the spectrum of secondary KIT mutations arising in GIST during imatinib therapy, demonstrating polyclonal resistance evolution and providing the rational basis for the development of broad-spectrum kinase inhibitors to overcome resistance.
German Interdisciplinary Sarcoma Group (GISG) Leadership
Co-founded and led the German Interdisciplinary Sarcoma Group (GISG), establishing a nationally coordinated clinical trials network that enabled German centers to contribute meaningfully to landmark global sarcoma and GIST trials.
Representative Works 代表性著作
Avapritinib in PDGFRA D842V-Mutant Unresectable or Metastatic GIST
Nature Medicine (2022)
Comprehensive analysis of the NAVIGATOR trial demonstrating exceptional response rates with avapritinib in PDGFRA D842V GIST, with molecular correlates of response and resistance.
Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumours (INVICTUS)
The Lancet Oncology (2020)
Phase III INVICTUS trial showing ripretinib improved progression-free survival versus placebo in heavily pretreated advanced GIST, establishing a new fourth-line standard of care.
Molecular mechanisms of secondary KIT resistance in imatinib-treated GIST
Journal of Clinical Oncology (2014)
Genomic analysis of sequential biopsies from GIST patients demonstrating polyclonal acquisition of secondary KIT kinase domain mutations as the dominant imatinib resistance mechanism.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Suzanne George
Dana-Farber Cancer Institute / Harvard Medical School
Marcia S. Brose
Sidney Kimmel Cancer Center, Thomas Jefferson University
Lori J. Wirth
Massachusetts General Hospital, Harvard Medical School
Steven I. Sherman
MD Anderson Cancer Center, University of Texas
关注 塞巴斯蒂安·鲍尔 的研究动态
Follow Sebastian Bauer's research updates
留下邮箱，当我们发布与 Sebastian Bauer（University Hospital Essen (Universitätsklinikum Essen)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment